Axsome Therapeutics(DE:19X)
€118.90-3.40 (-2.78%)
DE:19X
Axsome Therapeutics stock drug pipeline
€118.90
At close:-3.40 (-2.78%)
Axsome Therapeutics (19X) Drug Pipeline
5 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Axsome Therapeutics Inc. (DE:19X) have in its pipeline
Axsome Therapeutics DE:19X is currently developing the following drugs: Solriamfetol, Bupropion, Axs-05, Solriamfetol Dose A, Solriamfetol Dose B, Axs-14, Solriamfetol 150 Mg, Solriamfetol 75Mg, 150 Mg, Or 300 Mg, Axs-05, Solriamfetol 150 Mg, Solriamfetol 300 Mg, Solriamfetol 300 Mg, Axs-05, Bupropion, Axs-07, Axs-12, Meloxicam, Axs-07, Rizatriptan. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

